Resalis Therapeutics presented preclinical and early translational data for an antisense oligonucleotide targeting miR‑22 that the company says produces precision, durable weight loss by modulating fat metabolism rather than suppressing appetite. The ASO approach aims to avoid some long‑term drawbacks reported with GLP‑1 therapies, including effects on muscle and bone mass, according to Resalis’ scientists. At the same time, Novo Nordisk and Eli Lilly are expanding direct contracting and employer programs to control cost and widen access to GLP‑1 drugs. The dual storyline — novel oligo therapeutics and new commercial pathways — signals intensifying competition and distribution innovation in obesity care.